Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Convalescent sera, rich in pathogen-specific antibodies, offers passive immunity to patients with infectious diseases. Screening assays using convalescent sera are crucial for evaluating therapeutic efficacy, selecting suitable serum donors, and standardizing assays. They measure antibody levels, neutralizing potential, and specificity against viruses like SARS-CoV-2, ensuring therapeutic serum contains potent antibodies. Standardized procedures enable reliable results and wider adoption of serum therapy for COVID-19. We have developed a high-content image-based assay for screening convalescent sera against SARS-CoV-2 variants. Using various cell lines, we identified optimal candidates, employed immunofluorescence to visualize infected cells, and assessed neutralizing antibody efficacy. Screening convalescent sera for therapeutic potential identified neutralizing activity against SARS-CoV-2 variants. Dose–response analysis showed variable neutralizing activity, with some sera exhibiting broad neutralization. Additionally, we explored the synergy between neutralizing sera and β-d-N4-hydroxycytidine (NHC), an initial metabolite of molnupiravir. These assays enhance serum therapy’s benefits for COVID-19 treatment and aid in understanding neutralizing activity against SARS-CoV-2 variants, addressing viral challenges.

Details

Title
High-Throughput Screening Assay for Convalescent Sera in COVID-19: Efficacy, Donor Selection, and Variant Neutralization
Author
Kota, Krishna P 1 ; Trakht, Ilya 2 ; Kalantarov, Gavreel 2 ; Ordonez, David 1 ; Wei, Jiayi 1 ; Trefry, Stephanie 1 ; Bavari, Evia 1 ; Richardson, Jenny 1 ; Zamani, Rouzbeh 1 ; Raney, Christy 1 ; Nasar, Farooq 1 ; Daugherty, Bruce 1 ; Lederman, Seth 1   VIAFID ORCID Logo  ; Bavari, Sina 1 

 Tonix Pharmaceuticals, Frederick, MD 21701, USA; [email protected] (K.P.K.); [email protected] (D.O.); [email protected] (J.W.); [email protected] (E.B.); [email protected] (R.Z.); [email protected] (C.R.); [email protected] (F.N.); [email protected] (B.D.); [email protected] (S.L.) 
 Department of Medicine, Columbia University Medical Center, New York, NY 10032, USA; [email protected] (I.T.); [email protected] (G.K.) 
First page
1503
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
20762607
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3098047580
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.